

Abstract

The invention relates to the use of glucocorticoid receptor ligands selectively antagonizing the transactivation activity of the glucocorticoid receptor (GR) without affecting the transrepression activity. Compounds having this profile can be used as co-medication with conventional glucocorticoids in the treatment of inflammation and immune diseases. An advantage of this combination therapy is that metabolic side-effects of glucocorticoids are antagonized and only the anti-inflammatory or anti-immune activity of the glucocorticoids is maintained. In such a combination therapy, higher doses of the glucocorticoid can be used leading to better therapeutic efficacy.